Clevergene, a deep tech genomics company offering genetic diagnosis and discovery genomics solutions, received the PCPNDT (Pre-Conception and Pre-Natal Diagnostic Techniques) license and will now be offering prenatal diagnostics and preimplantation genetic screening tests.
With this certification Clevergene through its clinical diagnostics vertical The Gene Lab is launching a host of genetic tests that will improve outcomes of expectant parents and those planning a baby; these include Non Invasive Prenatal Testing (NIPT) for detecting chromosomal aneuploidy in foetuses, preimplantation genetic screening, Products of Conception (POC) genetic testing as well as genetic counselling services.
Recently Clevergene had augmented its capacity with the installation of the latest Illumina NovaSeq 6000 DNA sequencing platform. The introduction of these tests bolsters the existing suit of postnatal genetic diagnostics tests by The Gene Lab for inherited diseases as well as cancer. The NIPT tests will be able to examine cell-free DNA found in maternal blood originating from the foetus to screen for chromosome abnormalities, including Down syndrome, Edwards syndrome, Patau syndrome, and triploidy. The screening test can be performed as early as nine weeks of gestation and there is no risk to the foetus.
Speaking on this latest development Tony Jose, Co-Founder & CEO Clevergene said, through our offerings at The Gene Lab, it is our aim to improve patient outcomes by providing highly sensitive and accurate genetic tests at a rapid turnaround time. We are constantly expanding our suit of genomics-based tests for diagnosis, screening and prevention of genetic ailments.